<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02604823</url>
  </required_header>
  <id_info>
    <org_study_id>ML17700</org_study_id>
    <nct_id>NCT02604823</nct_id>
  </id_info>
  <brief_title>A Study of Peginterferon Alfa-2a (Pegasys) in Participants With Hepatitis B E-Antigen (HBeAg)-Positive Chronic Hepatitis B Virus (HBV)</brief_title>
  <official_title>Efficacy and Safety of Peginterferon Alfa-2a (40 KD) (Pegasys®) in Patients With HBeAg-Positive Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This is a study of the efficacy and safety of peginterferon alfa-2a (Pegasys) in naive,
      interferon- or lamivudine-pretreated participants with HBeAg-positive chronic HBV. Following
      48 weeks treatment, there will be a 24 week period of treatment-free follow-up. The
      anticipated time on study treatment is 3-12 months, and the target sample size is 100-500
      individuals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with HBV deoxyribonucleic acid (DNA) less than (&lt;) 100,000 copies per milliliters (copies/mL)</measure>
    <time_frame>72 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with HBeAg seroconversion</measure>
    <time_frame>72 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants who achieved HBV DNA levels below limit of detection</measure>
    <time_frame>Weeks 48 and 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with HBsAg loss</measure>
    <time_frame>Weeks 48 and 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with both Hepatitis B Surface Antigen (HBsAg) loss and presence of Anti-HBs</measure>
    <time_frame>Weeks 48 and 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with alanine aminotransferase (ALT) normalization</measure>
    <time_frame>Weeks 48 and 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with combined response (HBV DNA &lt;100,000 copies/mL, HBeAg loss, and ALT normalization)</measure>
    <time_frame>Weeks 48 and 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>up to 72 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">307</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Group A (Naïve Participants)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who never received any HBV treatment, will receive peginterferon alfa-2a (180 micrograms [mcg]) subcutaneously once weekly for 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (Conventional Interferon Pretreated Participants)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received conventional interferon treatment and had relapse or did not respond, will receive peginterferon alfa-2a (180 mcg) subcutaneously once weekly for 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C (Lamivudine Pretreated Participants)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received lamivudine and had relapse or did not respond, will receive peginterferon alfa-2a (180 mcg) subcutaneously once weekly for 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a</intervention_name>
    <description>Peginterferon alfa-2a will be administered at a dose of 180 mcg subcutaneously once weekly for 48 weeks.</description>
    <arm_group_label>Group A (Naïve Participants)</arm_group_label>
    <arm_group_label>Group B (Conventional Interferon Pretreated Participants)</arm_group_label>
    <arm_group_label>Group C (Lamivudine Pretreated Participants)</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult participants between 18 to 65 years of age

          -  HBeAg-positive chronic HBV

          -  Treatment-naive, or have received and have not responded to or have relapsed on either
             conventional interferon or lamivudine therapy.

        Exclusion Criteria:

          -  Antiviral or interferon-based therapy for chronic HBV within 6 months of enrollment

          -  Co-infection with active hepatitis A, C or D virus or with human immunodeficiency
             virus (HIV)

          -  Evidence of decompensated liver disease

          -  Medical condition associated with chronic liver disease other than viral hepatitis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Chair</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2015</study_first_submitted>
  <study_first_submitted_qc>November 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2015</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

